

Hideto Tamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8034470/publications.pdf>

Version: 2024-02-01

66
papers

6,080
citations

471509

17
h-index

214800

47
g-index

71
all docs

71
docs citations

71
times ranked

9824
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. <i>Nature Medicine</i> , 2002, 8, 793-800.	30.7	4,217
2	B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity. <i>Immunity</i> , 2003, 18, 849-861.	14.3	623
3	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. <i>Blood</i> , 2001, 97, 1809-1816.	1.4	201
4	Interferon- β and tumor necrosis factor- α induce an immunoinhibitory molecule, B7-H1, via nuclear factor- κ B activation in blasts in myelodysplastic syndromes. <i>Blood</i> , 2010, 116, 1124-1131.	1.4	179
5	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 363-370.	8.2	164
6	Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 5708-5717.	7.0	111
7	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. <i>Cancer Immunology Research</i> , 2016, 4, 779-788.	3.4	80
8	Immunopathogenesis and immunotherapy of multiple myeloma. <i>International Journal of Hematology</i> , 2018, 107, 278-285.	1.6	53
9	Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 88904-88917.	1.8	52
10	PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma. <i>Cancers</i> , 2020, 12, 924.	3.7	41
11	Immunology of B7-H1 and Its Roles in Human Diseases. <i>International Journal of Hematology</i> , 2003, 78, 321-328.	1.6	34
12	Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. <i>JCI Insight</i> , 2016, 1, e85061.	5.0	32
13	Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage. <i>Clinical Cancer Research</i> , 2009, 15, 770-777.	7.0	28
14	Clinical impact of serum soluble SLAMF7 in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34784-34793.	1.8	27
15	Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 986-990.	0.8	24
16	Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2019, 11, 2009.	3.7	20
17	Disease progression mechanism in myelodysplastic syndromes: Insight into the role of the microenvironment. <i>Leukemia Research</i> , 2011, 35, 1449-1452.	0.8	19
18	Increased apoptosis of circulating T cells in myelodysplastic syndromes. <i>Leukemia Research</i> , 2007, 31, 1641-1648.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study. <i>Leukemia Research</i> , 2012, 36, 1229-1236.	0.8	16
20	Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. <i>British Journal of Haematology</i> , 1996, 93, 45-52.	2.5	12
21	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. <i>Molecular Cancer Research</i> , 2020, 18, 632-643.	3.4	12
22	Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents™ era. <i>Annals of Hematology</i> , 2016, 95, 1465-1472.	1.8	11
23	Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. <i>Cancer Biomarkers</i> , 2016, 17, 21-32.	1.7	10
24	Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. <i>Leukemia and Lymphoma</i> , 2016, 57, 2204-2207.	1.3	9
25	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2142-2150.	2.2	9
26	CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. <i>Oncology Letters</i> , 2021, 23, 51.	1.8	9
27	Pure White Cell Aplasia: Report of the First Case Associated with Primary Biliary Cirrhosis. <i>International Journal of Hematology</i> , 2007, 85, 97-100.	1.6	8
28	Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 279.	3.7	8
29	Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia. , 1997, 55, 166-167.		6
30	Elotuzumab-induced interstitial lung disease: the first case report. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 491-494.	1.3	6
31	A combination of check-point blockade and Î±-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo. <i>Immunobiology</i> , 2020, 225, 151860.	1.9	5
32	The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma. <i>Experimental Hematology</i> , 2020, 90, 72-79.	0.4	5
33	Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report. <i>Allergology International</i> , 2017, 66, 497-498.	3.3	4
34	Expression and Function of B7.2 and B7-H2 Molecules on Myeloma Cells. <i>Blood</i> , 2008, 112, 2722-2722.	1.4	4
35	Retrospective analysis of prognostic factors for Waldenström macroglobulinemia: a multicenter cooperative study in Japan. <i>International Journal of Hematology</i> , 2017, 106, 681-690.	1.6	3
36	CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients. <i>Blood</i> , 2013, 122, 2799-2799.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Repeated Cycles of G-CSF-Combined Postremission Chemotherapy for Acute Myeloid Leukemia in a First Complete Remission: A Pilot Study. <i>Stem Cells</i> , 1998, 16, 280-287.	3.2	2
38	Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 249, 19-28.	1.2	2
39	Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine. <i>Blood</i> , 2014, 124, 4411-4411.	1.4	2
40	Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1283-1294.	4.1	1
41	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1
42	Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab. <i>Blood</i> , 2018, 132, 4439-4439.	1.4	1
43	Expression and Function of B7 Family Molecules on Blasts of Patients with Myelodysplastic Syndromes. <i>Journal of Nippon Medical School</i> , 2007, 74, 85-86.	0.9	1
44	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes: A Prospective Validation Study in Low-Risk Patients with Normal Karyotype. <i>Blood</i> , 2008, 112, 3634-3634.	1.4	1
45	FAILURE TO DETECT ANTI-HTLV-1 ANTIBODY IN A PATIENT WITH ADULT T-CELL LEUKAEMIA/LYMPHOMA. <i>British Journal of Haematology</i> , 1998, 103, 1207-1208.	2.5	1
46	Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. <i>Blood</i> , 2019, 134, 4361-4361.	1.4	1
47	Clinicopathologic characteristics and A20 mutation in primary thyroid lymphoma. <i>Journal of Nippon Medical School</i> , 2021, , .	0.9	1
48	Chronic Active Epstein-Barr Virus Infection Complicated with Acute Myeloid Leukemia, Squamous Cell Carcinoma and Diffuse Panbronchiolitis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2008, 97, 1081-1082.	0.0	0
49	Expression and Function of B7 Family Molecules in Hematologic Malignancies. <i>Journal of Nippon Medical School</i> , 2010, 77, 45-47.	0.9	0
50	Identification and Hematopoietic Potential of CD45-Negative Clonal Cells with Very Immature Phenotype (CD45 ⁺ CD34 ⁺ CD38 ⁺ Lin ⁻) in Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2004, 104, 3426-3426.	1.4	0
51	Flow Cytometric Characteristics of CD34+ Cells in Refractory Anemia: Their Diagnostic Value.. <i>Blood</i> , 2005, 106, 4896-4896.	1.4	0
52	B7.2 and B7-H2 Molecules Stimulate Proliferation of Myeloma Cells and Inhibit Anti-Myeloma Immune Responses.. <i>Blood</i> , 2007, 110, 3524-3524.	1.4	0
53	Expression of Functional B7-H1 Molecules on Blasts from Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 2429-2429.	1.4	0
54	Expression of WT-1 mRNA in Peripheral Blood from Myelodysplastic Syndromes. <i>Blood</i> , 2008, 112, 3637-3637.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Interferon- β and Tumor Necrosis Factor- α Induce An Immunoinhibitory Molecule, B7-H1, Via Nf κ B Activation in Blasts of Myelodysplastic Syndromes.. Blood, 2009, 114, 2766-2766.	1.4	0
56	Prognostic Significance of WT1 mRNA and Anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes.. Blood, 2009, 114, 3821-3821.	1.4	0
57	Clinical Features of AL Amyloidosis Diagnosed via Renal Biopsy, and Response to Treatment. Journal of Nippon Medical School, 2010, 77, 348-351.	0.9	0
58	B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior. Blood, 2011, 118, 474-474.	1.4	0
59	YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells. Blood, 2013, 122, 1667-1667.	1.4	0
60	Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma. Blood, 2013, 122, 4320-4320.	1.4	0
61	Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy. Blood, 2014, 124, 2018-2018.	1.4	0
62	Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma. Blood, 2014, 124, 2063-2063.	1.4	0
63	Retrospective Analysis of Prognostic Factors for Waldenström Macroglobulinemia: A Multicenter Cooperative Study in Japan. Blood, 2015, 126, 5028-5028.	1.4	0
64	Clinical Significance and Pathophysiological Function of the Tim-3/Galectin-9 Pathway in Myelodysplastic Syndromes. Blood, 2015, 126, 4117-4117.	1.4	0
65	A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma. Blood, 2018, 132, 5320-5320.	1.4	0
66	Effect of G-CSF on induction of ENA-78 and IL-8 in the patients with malignant lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal of Experimental Hematology / Chinese Association of Pathophysiology, 2014, 22, 344-8.	0.2	0